Apovia, Lorantis deal

Lorantis acquired HBV vaccine technology from Apovia, which is insolvent. The deal includes CV-1831, an HBV core antigen that uses the RC-529 adjuvant from Corixa Corp. (CRXA, Seattle, Wash.). CRXA a...